{
  "subject": "551286fbff22112efb467689d8850b850f2fb799b6b796a8c3d922e8153fcc57",
  "claims": [
    {
      "id": "title",
      "proposition": {
        "predicate": "title",
        "object": "Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "summary",
      "proposition": {
        "predicate": "summary",
        "object": "On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA."
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "url",
      "proposition": {
        "predicate": "url",
        "object": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "source-subject",
      "proposition": {
        "predicate": "source-subject",
        "object": "federal-register:2026-23075"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "source-edition",
      "proposition": {
        "predicate": "source-edition",
        "object": "ni:///sha-256;NNp5KeG2DxypvfVzczdRqsQ40m-nzVuxy4WKLB9JfTo"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "source-metadata",
      "proposition": {
        "predicate": "source-metadata",
        "object": {
          "subject": "federal-register:2026-23075",
          "revision": "ni:///sha-256;NNp5KeG2DxypvfVzczdRqsQ40m-nzVuxy4WKLB9JfTo",
          "documentNumber": "2026-23075",
          "documentUrl": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
          "title": "Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV",
          "documentType": "Rule",
          "publicationDate": "2026-11-12",
          "publicationDatePrecision": "civil-day",
          "agencies": [
            "Drug Enforcement Administration",
            "Justice Department"
          ],
          "abstract": "On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.",
          "commentsCloseOn": "2026-12-14",
          "commentDeadlineFieldRequested": true,
          "effectiveOn": "2026-11-12",
          "sourceAction": "Interim final rule; request for comments.",
          "federalRegisterCitation": "91 FR 72775",
          "docketIds": [
            "Docket No. DEA-1775"
          ],
          "regulationIdNumbers": [],
          "cfrReferences": [
            {
              "chapter": null,
              "citation_url": null,
              "part": "1308",
              "title": 21
            }
          ],
          "correctionOf": null,
          "corrections": [],
          "source": {
            "originalApiUrl": "https://www.federalregister.gov/api/v1/documents.json?conditions%5Bpublication_date%5D%5Bgte%5D=2026-11-05&conditions%5Bpublication_date%5D%5Blte%5D=2026-11-12&per_page=100&page=1&order=newest&fields%5B%5D=document_number&fields%5B%5D=title&fields%5B%5D=type&fields%5B%5D=abstract&fields%5B%5D=html_url&fields%5B%5D=publication_date&fields%5B%5D=agencies&fields%5B%5D=comments_close_on&fields%5B%5D=effective_on&fields%5B%5D=action&fields%5B%5D=citation&fields%5B%5D=regulation_id_numbers&fields%5B%5D=cfr_references&fields%5B%5D=docket_ids&fields%5B%5D=correction_of&fields%5B%5D=corrections",
            "originalResponseDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef",
            "originalResponseUri": "ni:///sha-256;4JX-tbnIloxF8RNyDmPIIrp_uzr9_sBpa65GvcIE-e8",
            "normalizedLotDigest": "sha256:d3ff8e93b6fed45c9386d3c7086e789c7bc9c64bff674c189560c92a5daaf952",
            "observedAt": "2026-11-12T21:30:47.088Z",
            "provider": "https://www.federalregister.gov",
            "publisher": {
              "name": "Office of the Federal Register",
              "source": "https://www.federalregister.gov/reader-aids/developer-resources/rest-api",
              "reproduction": "https://www.archives.gov/federal-register/faqs",
              "officialNotice": "The source Federal Register edition, not this derived JSON, is authoritative. No government endorsement."
            },
            "evidenceClass": "source-dated government metadata, independently replayable from original HTTP bytes held by the source acquisition run"
          }
        }
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    },
    {
      "id": "editorial-standing",
      "proposition": {
        "predicate": "editorial-standing",
        "object": "source metadata; editorial acceptance pending"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv",
        "sourceDigest": "sha256:e095feb5b9c8968c45f113720e63c822ba7fbb3afdfec0696bae46bdc204f9ef"
      },
      "status": "unverified"
    }
  ]
}
